UC73: Generic Substitution Advisor

The Problem

When a new generic drug launches (FDA approves the first generic version of a brand-name drug), significant cost savings become available. A drug costing $500/month as a brand medication may cost $20/month as a generic, benefiting patients, PBMs, and insurers. However, prescribers and patients are often unaware of new generic availability; they continue prescribing/filling brand medication unnecessarily. Identifying patients on brand drugs with newly-available generics requires monitoring FDA Orange Book approvals and cross-referencing against active prescriptions across millions of patients,a task that is computationally intensive and time-consuming. Without proactive notification, the cost-saving opportunity is lost.

What the Agent Does

FDA Orange Book Monitoring: Continuously monitors FDA Orange Book (database of approved generic medications); identifies each newly-approved generic with equivalent therapeutic effect to brand medication.
Patient Impact Analysis: Cross-references newly-available generics against PBM claims data; identifies patients currently filling brand medication for which a new generic is now available; quantifies per-patient monthly savings (e.g., "Patient saves $480/month switching from BrandX to GenericX").
Prescriber Notification: For high-impact generics (significant cost savings, high-volume of patients affected), generates prescriber notifications explaining new generic availability and patient savings; delivers via EHR message or fax with clinical evidence supporting equivalence.
Patient Education Campaign: Generates patient-facing messaging (SMS, email, mail notification) explaining new generic option, cost savings, and process for switching (e.g., "Ask your pharmacist about the new generic"). Messaging calibrated to patient health literacy.
Formulary Coordination: Works with PBM formulary team to ensure new generic is placed on preferred tier (to incentivize utilization); recommends brand medication tier adjustment if appropriate.
Savings Tracking: Tracks adoption of new generic among notified patients; calculates realized cost savings; generates compliance reports for PBM leadership.

Data Requirements

Aspect	Details
Data Sources	FDA Orange Book database (updated weekly), PBM prescription claims data (5+ years), formulary tier data, patient contact information, drug equivalency data (bioavailability, therapeutic equivalence code).
Data Classification	PHI (prescription history, cost information), proprietary claims data
Data Quality Needs	High , Orange Book data must be current (weekly updates); claims data must be complete and recent; equivalency codes must be accurate.
Complexity	Moderate , database monitoring straightforward; patient matching straightforward; savings calculations straightforward.

Score Breakdown

Criterion	Weight	Score (1-5)	Weighted
Time Recaptured	15%	5	0.75
Error Reduction	10%	4	0.40
Cost Avoidance	10%	4	0.40
Strategic Leverage	5%	4	0.20
Data Availability	15%	4	0.60
Process Clarity	15%	4	0.60
Ease of Implementation	10%	4	0.40
Fallback Available	10%	4	0.40
Audience (Int/Ext)	10%	4	0.40
Composite	100%		4.05

Why It Scores Well

Quantifiable, Immediate Impact: Each new generic generates measurable cost savings; ROI is direct and large-scale.
Multi-Stakeholder Alignment: Patients, prescribers, PBMs all benefit from generic availability; strong incentive alignment.
Scalable & Automated: Logic applies uniformly across thousands of drugs and millions of patients; easily scaled.
Low Complexity, High Value: Despite moderate technical complexity, the financial impact is enormous,even modest adoption rates yield millions in savings.
Continuous Opportunity: FDA approves new generics weekly; ongoing revenue impact.
Proven Evidence: Generic bioequivalence is clinically established; no new clinical evidence required.

Regulatory Alignment

FDA Generic Equivalence: Agent only recommends switches to FDA-approved generics with demonstrated bioequivalence; no clinical risk.
Prescriber Authority: Prescriber retains authority to approve generic substitution; agent provides recommendation only.
Patient Choice: Patients can opt-in or opt-out of generic switching; informed consent maintained.
Insurance Regulations: Generic tiering recommendations respect payer-specific constraints.

Sprint Factory Fit

Very High Fit. Orange Book monitoring is straightforward API integration. Claims data matching is standard data engineering. Savings calculations are simple math. Initial build: 2 to 3 weeks for Orange Book monitoring + patient matching + savings calculation. Prescriber notification: 1 week for template generation + EHR integration. Patient notifications: 1 week for SMS/email integration. Deployment: Batch job running weekly + prescriber/patient notification system. Very low ongoing maintenance.

Comparable Implementations

FDA Orange Book Database , Official generic database reference.
PBM Analytics Platforms , Savings tracking baseline.
Express Scripts Generic Monitoring Programs , Implementation reference.

Deploy This Use Case with the Sprint Factory

From zero to a governed, production agent in 6 weeks.

Sprint Factory Schedule a Briefing

Related Use Cases

Batch Claims Operations

Claims Auto-Adjudication Sentinel

Score: 4.3/5.0

Batch Finance & Actuarial

Risk Adjustment (HCC) Capture Agent

Score: 4.2/5.0

Batch Quality & Compliance

HEDIS Quality Score Monitor

Score: 4.15/5.0

Governance Risks to Consider

Before deploying this use case, review these agentic AI risks from the Corvair Risk Catalogue. Each is scored on the DAMAGE framework and mapped to regulatory expectations.